Retinal Drug Toxicity and Efficacy Studies - Newcells

Retinal platform

An in vitro, light responsive, retinal model for accurate predictions of in vivo outcomes you can have confidence in.

aProximateTM

Kidney platform

The most advanced near-physiological high throughput kidney proximal tubule cells (PTC) model to investigate drug transport modalities in vitro.

Lung epithelia model

Lung model

A model to investigate airway physiology, viral infection, drug safety and environmental impacts on lung airway epithelia.

Sinusoid iPSC-derived Liver model

Liver model

We are developing a model of liver sinusoid derived from human induced pluripotent stem cells (iPSC).

Retinal Drug Toxicity and Efficacy Studies

Retinal drug toxicity and efficacy

Retinal drug toxicity is a relatively uncommon occurrence but with potential life-changing impact for patients. Most in vitro pre-clinical models for testing drug safety and efficacy are poor representations of the complex human retina. Newcells iPSC-derived retinal organoids and RPE is a platform used for more accurate in vitro to in vivo extrapolation (IVIVE). It also enables screening of new drugs and therapies for the retina.

  • Modelling retinal drug toxicity: this has been tested for the response to known toxins such as thioridazine and doxorubicin. The intrinsic fluorescence of doxorubicin facilitates visualisation of the drug penetration. (A) Exposure of the iPSC-derived retinal organoids to doxorubicin reduces cell viability in a dose-dependent manner (B). 
(A) Newcells human iPSC-derived retinal organoids are permeable to small molecules: 4 to 24h time course showing the increased penetration of doxorubicin, a naturally fluorescent small toxic molecule (red) into the retinal organoid.
(B) Dose response of Newcells human iPSC-derived retinal organoids to doxorubicin. The retinal organoids were treated with increasing dose of doxorubicin over 24h and cell viability was measured using a ATP assay. A decrease in cell viability was observed following exposure to the drug.

  • Screening Tool: Newcells retinal organoids can be used for in vitro drug screening during drug development to evaluate retinal toxicity. The dose response of a drug can be measured with retinal organoids showing an effect for cytotoxic drugs, while known non-toxic drugs do not affect organoid viability (C).   
(C) Dose-response plots of known cytotoxic and non-cytotoxic retinal agents determined in ROs using CellTiter-Glo® 3D ATP assay after 72 h.  

More information on the retinal platform

Have any questions? Check out our Frequently Asked Questions.